JKJessica Kasza

Jessica Kasza

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jessica Kasza has a total of 327 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Statistical analysis plan for a stepped-wedge cluster randomized clinical trial for the evaluation of the clinical impact of different telemedicine practices in intensive care units – TELESCOPE 2 trial

    by Tiago Mendonça dos Santos, Renato Carneiro de Freitas Chaves, Bruna Gomes Barbeiro, Maura Cristina dos Santos, Thiago Domingos Corrêa, Alexandre Biasi Cavalcanti, Ary Serpa, Carlos Henrique Sartorato Pedrotti, Fernando Godinho Zampieri, Guilherme de Paula Pinto Schettino, et al.

    Background The optimal model for delivering Tele-ICU is still to be determined. In the TELE-critical Care verSus usual Care on ICU Performance (TELESCOPE) trial, implementing medical-led daily multidisciplinary rounds did not show evidence of improved clinical outcomes. The TELESCOPE 2 trial was therefore designed to evaluate whether expanding this model to include a structured […] ABSTRACT Background The optimal model for delivering Tele-ICU is still to be determined. In the TELE-critical Care verSus usual Care on ICU Performance (TELESCOPE) trial, implementing medical-led daily multidisciplinary rounds did not show evidence of improved clinical outcomes. The TELESCOPE 2 trial was therefore designed to evaluate whether expanding this model to include a structured […]

  • Open Access

    A classification of incomplete stepped wedge cluster randomised trial designs

    by Ehsan Rezaei-Darzi, Andrew B Forbes, Kelsey L Grantham, Jessica Kasza

    Background/aims: Stepped wedge designs are cluster randomised trial designs for testing new interventions through a phased rollout of the intervention across clusters. In many trial settings, a complete stepped wedge design can place a substantial burden on clusters by requiring data collection over the entire trial duration. Incomplete stepped wedge designs, for example, “staircase designs,” where clusters collect data for a limited duration of time, are frequently used to overcome this issue. However, the term “incomplete stepped wedge design” is also used when transition or implementation periods are incorporated in an otherwise complete stepped wedge design. Thus, “incomplete” is an imprecise term that does not convey any specific design characteristics. Methods: We introduce terminology to enable a classification of incomplete stepped wedge designs, with a particular focus on different variants of staircase designs. Results: We provide definitions of variants of staircase designs with their sub-variants. We also describe two types of mid-sequence breaks in data collection: inter-treatment breaks occurring between control and intervention durations of data collection (i.e. implementation or transition periods), and intra-treatment breaks occurring between durations of data collection under the same treatment condition. These breaks introduce different forms of incompleteness into designs. Conclusion: Through the use of this terminology and associated classifications, trialists can more clearly communicate the way in which their “incomplete stepped wedge design” is incomplete, and health researchers can classify trials in systematic reviews involving complete stepped wedge designs and any incomplete variants.

  • Open Access

    What is estimated in cluster randomized crossover trials with informative sizes? A survey of estimands and common estimators

    by Kenneth M Lee, Andrew B Forbes, Jessica Kasza, Andrew Copas, Brennan C Kahan, Paul J Young, Michael O Harhay, Fan Li

    The cluster randomized crossover (CRXO) trial, among other multi-period cluster randomized trial designs, can target average treatment effect (ATE) estimands that equally weigh the contributions of individuals (iATE), clusters (cATE), cluster-periods (cpATE), or periods (pATE). With these weighted ATE estimands, we define different forms of informative sizes, where the treatment effects vary according to cluster, period, and/or cluster-period sizes, causing these estimands to differ. Under such informative sizes, we survey which of the unweighted, inverse cluster-period size weighted, inverse cluster size weighted, and inverse period size weighted: (i) independence estimating equation, (ii) fixed effects model, (iii) exchangeable mixed effects model, and (iv) nested exchangeable mixed effects model treatment effect estimators are consistent for the aforementioned estimands in cross-sectional CRXO designs with continuous outcomes. We demonstrate that with informative sizes, the unweighted and weighted nested exchangeable mixed effects model estimators are not consistent for any meaningful estimand and can yield biased results. In contrast, the unweighted and weighted independence estimating equation, and under specific scenarios, the fixed effects model and exchangeable mixed effects model, can yield consistent and empirically unbiased estimators for meaningful estimands in CRXO trials.


  • Open Access

    Small numbers of clusters in cluster randomised trials: a scoping review of problems and proposed solutions

    by Olivier Quintin, Jessica Kasza, Nathan Davies, Sarah Markham, Richard Hooper

  • Reducing Bias in Cluster Randomized Trials in Nephrology

    by Jessica Kasza, Gabor Mihala, Agnès Caille, Rhys Bowden

  • Open Access

    Additional crossovers in cluster randomised crossover trials do not always increase statistical power

    by Km Tanvir, Andrew B Forbes, Kelsey L Grantham, Jessica Kasza

    Background: Cluster randomised crossover designs (CRXOs) are a powerful type of longitudinal cluster randomised trial in which all participating clusters switch between two treatment conditions. “Multiple-period” CRXOs divide the trial duration into a number of periods of equal length and can allow for multiple crossovers between treatment conditions. It can be assumed that increasing the number of crossovers leads to an increase in statistical power. We investigate whether this is true for standard correlation structures, comparing CRXO designs with equal numbers of clusters, participants, and periods but differing in the number of crossovers, considering continuous outcomes. Methods: We consider the formula for the variance of the treatment effect estimator for multiple-period CRXOs under exchangeable and block-exchangeable within-cluster correlation structures, assuming equal cluster-period sizes and different patterns of treatment conditions in the treatment sequences varying in the number of crossovers. We also conduct a simulation study to compare the statistical power between multiple-period CRXO designs with different numbers of crossovers that share the same number and duration of periods and the same number of participants in each cluster period. Results: Under exchangeable and block-exchangeable correlation structures and equal cluster-period sizes, the number of crossovers in the treatment sequences does not impact study power, provided the design is balanced in terms of the number of periods and clusters implementing each condition. Conclusions: When an exchangeable or block-exchangeable within-cluster correlation structure and a time-invariant effect of treatment are assumed, power calculations for CRXO designs are invariant to the specific ordering of treatment conditions. In particular, a CRXO design with additional crossovers does not lead to increased statistical power compared to a CRXO design with just one crossover for these within-cluster correlation structures. Further work is required to investigate the utility of multiple crossovers in situations where the treatment effect varies over time.

  • Open Access

    Comparing meta-analysis and linear mixed model-based approaches for the analysis of continuous outcomes from batched stepped wedge trials

    by Dixon Orlando, Rhys Bowden, Kelsey L Grantham, Joanne E McKenzie, Andrew B Forbes, Jessica Kasza

    Background: Stepped wedge designs are a specific type of cluster randomised trial design that requires all clusters to start and end the study at the same time. Batched stepped wedge designs are a variant that allows clusters to commence the study in batches instead of all at once. Since different batches of clusters may have different characteristics, it is possible that the treatment effect differs across batches. Here, we explore different approaches for accommodating this treatment effect heterogeneity when analysing data from a batched stepped wedge design where each participant provides a single outcome measurement: linear mixed models with a random coefficient for the intervention for each batch of clusters with estimation via restricted maximum likelihood; and meta-analysis approaches that pool the batch-specific treatment effect estimates using fixed- or random-effects meta-analysis approaches. In many batched stepped wedge designs, the number of batches will be low (e.g. 2); it is unclear what impact the small number of batches may have on bias and confidence interval coverage of these approaches. Methods: We simulated continuous outcome data from a range of batched stepped wedge designs with two and five batches, different within-cluster correlation structures (exchangeable, block-exchangeable), with and without period effects shared across batches, and with and without treatment effect heterogeneity across batches. Using the ‘lme4’ and ‘meta’ packages in R 4.4.1, we analysed each simulated data set using both linear mixed effects models (with and without treatment effect heterogeneity) and a range of meta-analysis approaches. We assessed the relative performance of all methods to estimate the true treatment effect using rates of convergence, bias, confidence interval coverage, and empirical standard error. Results: Treatment effect estimates from all meta-analysis approaches were unbiased. When period effects were incorrectly specified, treatment effects from linear mixed effects models were biased; when correctly specified, treatment effect estimates from these models were unbiased. Confidence interval coverage was similar for all random-effects meta-analysis approaches and close to the nominal level. For fixed-effect meta-analysis and linear mixed models, coverage depended on whether treatment effect heterogeneity was present. Conclusion: When batched stepped wedge trials include a small number of batches (two and five batches), linear mixed models provide unbiased estimates of treatment effects when correctly specified, but exhibit under-coverage of confidence intervals when treatment effect heterogeneity is present. Random-effects meta-analysis approaches provide unbiased estimates and nominal confidence interval coverage whether or not period or treatment effects vary across batches, but can yield excessively wide confidence intervals. When batched stepped wedge trials include small numbers of batches, we recommend the use of random-effects meta-analysis approaches for the analysis of continuous outcomes.

  • Open Access

    Small numbers of clusters in cluster randomised trials: a scoping review of problems and proposed solutions

    by Olivier Quintin, J Kasza, Nathan Davies, Sarah Markham, Richard Hooper

    ObjectivesCluster randomised trials (CRTs) are commonly used to evaluate healthcare interventions and policies in “real-world” settings. Many CRTs include only a limited number of clusters for practical, logistical, or methodological reasons. Small numbers of clusters are associated with known analytical and design challenges, though there is little consensus on exactly what constitutes a “small” number in practice. Identifying problems and potential solutions will help researchers plan more effective evaluations.MethodsWe performed a scoping review of the literature to identify any problems and/or potential solutions related to small numbers of clusters for any type of CRT. We identified 53 references from the Ovid, MedLine and Embase databases.ResultsMost articles focus specifically either on parallel group CRTs or on stepped wedge CRTs (17 (32.1%) sources each). Challenges related to Type I error rate inflation or other inferential issues are identified in 32 (60.4%) sources, and the risk of covariate imbalance between trial arms in 30 (56.6%), making these the most commonly mentioned problems. A variety of methods to control Type I error rate inflation have been proposed, but with some concerns raised over their performance down to very small numbers of clusters. Operational definitions of a “small” number of clusters vary considerably across the literature from 3 to 50 (median 20). Most published stepped wedge trials, in particular, are what most methodological articles would call small (in terms of number of clusters).ConclusionsWork on mitigating the problems arising from small numbers of clusters has tended to focus on the analysis of CRTs rather than their design (e.g. sample size justification) or conduct. Further work is still needed to develop simple, practical guidance to help triallists understand what challenges they will face and when, and how to optimise the performance of methods for CRTs with limited numbers of clusters.

  • Open Access

    An online sample size calculator for designing partially clustered trials

    by Kylie M Lange, Thomas R Sullivan, Jessica Kasza, Lisa N Yelland

    Background: Partially clustered trials are trials that, by design, include a mixture of independent and clustered observations. For example, neonatal trials may include infants from a single, twin or triplet birth. The clustering of observations in partially clustered trials should be accounted for when determining the target sample size to avoid treatment arm comparisons being over or under powered. Limited tools are currently available for calculating the sample size for partially clustered trials, particularly when the maximum cluster size is greater than 2. The aim of this article is to introduce a new online application to calculate the target sample size for partially clustered trials covering a broad range of scenarios. Methods: The target sample size is calculated using design effects recently derived for two-arm partially clustered trials when the clusters exist prior to randomisation and the outcome of interest is continuous or binary. Both cluster and individual randomisation are considered for the clustered observations (resulting in nested and crossed designs, respectively). The sample size depends on quantities needed for typical sample size calculations, such as the effect size of interest, and the desired significance level and power. In addition, the sample size for partially clustered trials also depends on the range of cluster sizes, the proportion of observations that belong to clusters of each size, the intracluster correlation coefficient, the method of randomisation for the clustered observations, and the model that will be used for analysis. We developed an R Shiny web application that implements these methods in an easy-to-use sample size calculator that is freely available online. Results: The sample size calculator is free to access and provides trialists with the ability to determine the target sample size for different types of partially clustered trials. Step-by-step instructions are provided to illustrate the use of the calculator for designing two hypothetical trials. The target sample size that accounts for partial clustering can be quite different to the sample size that is calculated by methods for an independent design that ignore the clustering. Conclusion: Partial clustering affects the power and sample size requirements of clinical trials. The calculator presented in this article allows trialists to account for the clustering that occurs in two-arm partially clustered trials for binary and continuous outcomes and ensure their trials are appropriately powered.


  • Open Access

    Repeated inclusion cluster randomized trials: a new class of designs for assessing group-level interventions

    by Jessica Kasza, Kelsey L Grantham, Rhys Bowden, Brennan C Kahan, Andrew B Forbes

    Individually randomized trials allow participants to be included in a trial multiple times, with independent randomization at each inclusion. Often referred to as re-randomization designs, these trials have been shown to increase trial recruitment rates. Treatment effect estimators remain unbiased but are more precise than for designs with more participants but no repeat inclusions, but do rely on additional assumptions. Here, we introduce a new class of cluster randomized trial designs: repeated inclusion cluster randomized trials, where some clusters are randomized serially in the same trial. The trial in which clusters are initially included may have a standard cluster randomized design or a longitudinal variant, such as a cluster randomized crossover design. Allowing clusters to participate multiple times in the same trial could reduce the need to recruit new clusters; useful when cluster recruitment is difficult. Assuming a constant treatment effect across repeated inclusions, we show that when equal numbers of clusters and participants are included in each treatment group in each study period, power will be the same or higher as for a similar trial where clusters are not re-randomized but which has the same total number of measurements. Whether power is maintained or increased depends on the study design and the within-cluster correlation structure; increasing the number of within-cluster comparisons increases study power.